Gun-Wook Kang
Directeur/Membre du Conseil chez KOREA UNITED PHARM INC.
Postes actifs de Gun-Wook Kang
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| KOREA UNITED PHARM INC. | Directeur/Membre du Conseil | - | - |
| Independent Dir/Board Member | - | - | |
| Seoul National University | Corporate Officer/Principal | - | - |
Pelemed Co., Ltd.
 Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Directeur/Membre du Conseil | - | - |
| Independent Dir/Board Member | - | - |
Historique de carrière de Gun-Wook Kang
Statistiques
Internationale
| Corée du Sud | 4 |
Opérationnelle
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KOREA UNITED PHARM INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Pelemed Co., Ltd.
Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Health Technology |
- Bourse
- Insiders
- Gun-Wook Kang
- Expérience
